The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: Cytoplasmic determinants of Vpu function

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Kluge, Silvia F ^a   Sauter, Daniel ^a   Vogl, Michael ^a   Peeters, Martine ^b   Li, Yingying ^c   Bibollet Ruche, Frederic ^c   Hahn, Beatrice H ^c   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD4 ANTIGEN; CHIMERIC PROTEIN; MEMBRANE PROTEIN; PROTEIN DSGXXS BETA TRCP; TETHERIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPU PROTEIN;

ARTICLE; BINDING SITE; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSMEMBRANE DOMAIN; VIRUS RELEASE; VIRUS STRAIN;

ANIMALS; ANTIGENS, CD; CELL LINE; GORILLA GORILLA; GPI-LINKED PROTEINS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PAN TROGLODYTES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

HUMAN IMMUNODEFICIENCY VIRUS 1; PAN; PAN TROGLODYTES TROGLODYTES;

EID: 84875057927     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-32     Document Type: Article

References (56)

1. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012, 287:40875-40883. 10.1074/jbc.R112.416925, 23043100.
2. Blanco-Melo D, Venkatesh S, Bieniasz PD. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 2012, 37:399-411. 10.1016/j.immuni.2012.08.013, 22999946.
3. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2012, 2:a006940. 3331687, 22553496.
4. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010, 8:55-67. 10.1016/j.chom.2010.06.004, 20638642.
5. Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T. Primate lentivirus capsid sensitivity to TRIM5 proteins. J Virol 2008, 82:6772-6777. 10.1128/JVI.00410-08, 2447065, 18417575.
6. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853. 10.1038/nature02343, 14985764.
7. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C, Diaz-Griffero F. RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J Virol 2012, 86:1717-1727. 10.1128/JVI.05811-11, 3264337, 22114335.
8. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH. Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol 2004, 78:12041-12046. 10.1128/JVI.78.21.12041-12046.2004, 523299, 15479843.
9. Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim K-A, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421. 10.1016/j.chom.2009.10.004, 2779047, 19917496.
10. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5:e1000429. 10.1371/journal.ppat.1000429, 2673686, 19436700.
11. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6:54-67. 10.1016/j.chom.2009.05.008, 2852097, 19501037.
12. Sauter D, Specht A, Kirchhoff F. Tetherin: holding on and letting go. Cell 2010, 141:392-398. 10.1016/j.cell.2010.04.022, 20434978.
13. Sharp PM, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci 2010, 365:2487-2494. 10.1098/rstb.2010.0031, 2935100, 20643738.
14. Plantier J-C, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15:871-872. 10.1038/nm.2016, 19648927.
15. Sauter D, Hué S, Petit SJ, Plantier J-C, Towers GJ, Kirchhoff F, Gupta RK. HIV-1 Group P is unable to antagonize human tetherin by Vpu. Env or Nef. Retrovirology 2011, 8:103. 10.1186/1742-4690-8-103, 3285029, 22171785.
16. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 2012, 8:e1003093. 10.1371/journal.ppat.1003093, 3534379, 23308067.
17. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JFY, Sharp PM, Shaw GM, Peeters M, Hahn BH. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526. 10.1126/science.1126531, 2442710, 16728595.
18. Takehisa J, Kraus MH, Ayouba A, Bailes E, Van Heuverswyn F, Decker JM, Li Y, Rudicell RS, Learn GH, Neel C, Ngole EM, Shaw GM, Peeters M, Sharp PM, Hahn BH. Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol 2009, 83:1635-1648. 10.1128/JVI.02311-08, 2643789, 19073717.
19. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, Peeters M. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444:164. 10.1038/444164a, 17093443.
20. Li Y, Ndjango J-B, Learn GH, Ramirez MA, Keele BF, Bibollet-Ruche F, Liu W, Easlick JL, Decker JM, Rudicell RS, Inogwabini B-I, Ahuka-Mundeke S, Leendertz FH, Reynolds V, Muller MN, Chancellor RL, Rundus AS, Simmons N, Worobey M, Shaw GM, Peeters M, Sharp PM, Hahn BH. Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir. J Virol 2012, 86:10776-10791. 10.1128/JVI.01498-12, 3457319, 22837215.
21. Kueck T, Neil SJD. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 2012, 8:e1002609. 10.1371/journal.ppat.1002609, 3315493, 22479182.
22. Petit SJ, Blondeau C, Towers GJ. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol 2011, 92:2937-2948. 10.1099/vir.0.035931-0, 21900423.
23. Ruiz A, Hill MS, Schmitt K, Guatelli J, Stephens EB. Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release. Virology 2008, 378:58-68. 10.1016/j.virol.2008.05.022, 18579178.
24. Dubé M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010, 6:e1000856. 10.1371/journal.ppat.1000856, 2851737, 20386718.
25. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011, 1:a006841. 3234451, 22229120.
26. Vigan R, Neil SJD. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol 2011, 85:9737-9748. 10.1128/JVI.00479-11, 3196455, 21775465.
27. Andrew A, Strebel K. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med 2010, 31:407-417. 10.1016/j.mam.2010.08.002, 2967615, 20858517.
28. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 2009, 5:e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
29. Kanemori Y, Uto K, Sagata N. Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci U S A 2005, 102:6279-6284. 10.1073/pnas.0501873102, 1083676, 15845771.
30. Bour S, Schubert U, Strebel K. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 1995, 69:1510-1520. 188742, 7853484.
31. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200. 240416, 1433512.
32. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1:565-574. 10.1016/S1097-2765(00)80056-8, 9660940.
33. Villalobos V, Naik S, Bruinsma M, Dothager RS, Pan M-H, Samrakandi M, Moss B, Elhammali A, Piwnica-Worms D. Dual-color click beetle luciferase heteroprotein fragment complementation assays. Chem Biol 2010, 17:1018-1029. 10.1016/j.chembiol.2010.06.018, 2943495, 20851351.
34. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Früh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009, 83:7931-7947. 10.1128/JVI.00242-09, 2715753, 19515779.
35. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009, 5:e1000574. 10.1371/journal.ppat.1000574, 2729927, 19730691.
36. Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP, Ebina H, Strebel K, Sato H, Koyanagi Y. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 2011, 85:932-945. 10.1128/JVI.01668-10, 3020002, 21068238.
37. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067. 10.1016/j.cell.2006.04.033, 16777597.
38. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx PA, Hahn BH, Sharp PM. Hybrid origin of SIV in chimpanzees. Science 2003, 300:1713. 10.1126/science.1080657, 12805540.
39. Moll M, Andersson SK, Smed-Sörensen A, Sandberg JK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 2010, 116:1876-1884. 10.1182/blood-2009-09-243667, 3173986, 20530791.
40. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010, 8:397-409. 10.1016/j.chom.2010.10.008, 3005698, 21075351.
41. Doehle BP, Chang K, Rustagi A, McNevin J, McElrath MJ, Gale M. Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol 2012, 86:8367-8374. 10.1128/JVI.00423-12, 3421752, 22593165.
42. Götz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A, Geyer M, Bibollet-Ruche F, Learn GH, Fackler OT, Hahn BH, Kirchhoff F. Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 2012, 12:373-380. 10.1016/j.chom.2012.07.008, 22980333.
43. Kirchhoff F, Schindler M, Bailer N, Renkema GH, Saksela K, Knoop V, Müller-Trutwin MC, Santiago ML, Bibollet-Ruche F, Dittmar MT, Heeney JL, Hahn BH, Münch J. Nef proteins from simian immunodeficiency virus-infected chimpanzees interact with p21-activated kinase 2 and modulate cell surface expression of various human receptors. J Virol 2004, 78:6864-6874. 10.1128/JVI.78.13.6864-6874.2004, 421647, 15194762.
44. Münch J, Schindler M, Wildum S, Rücker E, Bailer N, Knoop V, Novembre FJ, Kirchhoff F. Primary sooty mangabey simian immunodeficiency virus and human immunodeficiency virus type 2 nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication. J Virol 2005, 79:10547-10560. 10.1128/JVI.79.16.10547-10560.2005, 1182674, 16051847.
45. Paul M, Jabbar MA. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 1997, 232:207-216. 10.1006/viro.1997.8541, 9185604.
46. Boll W, Rapoport I, Brunner C, Modis Y, Prehn S, Kirchhausen T. The mu2 subunit of the clathrin adaptor AP-2 binds to FDNPVY and YppØ sorting signals at distinct sites. Traffic 2002, 3:590-600. 10.1034/j.1600-0854.2002.30808.x, 12121421.
47. Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem 1990, 265:3116-3123.
48. Backer JM, Kahn CR, Cahill DA, Ullrich A, White MF. Receptor-mediated internalization of insulin requires a 12-amino acid sequence in the juxtamembrane region of the insulin receptor beta-subunit. J Biol Chem 1990, 265:16450-16454.
49. Lim ES, Malik HS, Emerman M. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 2010, 84:7124-7134. 10.1128/JVI.00468-10, 2898239, 20444900.
50. Gupta RK, Towers GJ. A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe 2009, 6:393-395. 10.1016/j.chom.2009.11.002, 3556580, 19917491.
51. Papkalla A, Münch J, Otto C, Kirchhoff F. Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 2002, 76:8455-8459. 10.1128/JVI.76.16.8455-8459.2002, 155138, 12134048.
52. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000, 74:8358-8367. 10.1128/JVI.74.18.8358-8367.2000, 116346, 10954535.
53. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864. 109730, 9525605.
54. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905. 10.1128/AAC.46.6.1896-1905.2002, 127242, 12019106.
55. Münch J, Rajan D, Schindler M, Specht A, Rücker E, Novembre FJ, Nerrienet E, Müller-Trutwin MC, Peeters M, Hahn BH, Kirchhoff F. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007, 81:13852-13864. 10.1128/JVI.00904-07, 2168858, 17928336.
56. Schindler M, Würfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Münch J, Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003, 77:10548-10556. 10.1128/JVI.77.19.10548-10556.2003, 228419, 12970439.